• AML
  • Qui Tam
  • SEC
  • CFTC
  • FCPA
  • FAQS
Subscribe
Donate
No Result
View All Result
Whistleblower Network News
The Truth at Any Cost.
Qui Tam, Compliance and Anti-Corruption News.
Whistleblower Network News
No Result
View All Result
Home False Claims-Qui Tam

Two Recent Healthcare FCA Settlements, Whistleblowers Awarded in Both Cases

Ana PopovichbyAna Popovich
July 26, 2022
in False Claims-Qui Tam
Reading Time: 5 mins read
3-d graphic of a caduceus
Share on TwitterShare on FacebookShare on LinkedInEmail

The U.S. Department of Justice (DOJ) recently announced two large settlements in cases that stemmed from qui tam, or whistleblower, lawsuits. Both cases involve the healthcare industry: one case is a settlement with a clinical laboratory and the other is a settlement with a medical device manufacturer.

The qui tam provisions of the False Claims Act enable private citizens to file lawsuits on behalf of the government if they know of an individual or company defrauding the government. Qui tam whistleblowers are eligible to receive between 15 and 30% of the government’s recovery, if one occurs.

Inform Diagnostics, Inc.

The DOJ announced on July 20 that Inform Diagnostics, Inc., a clinical laboratory that “provides anatomic pathology services to physician practices” in the U.S., will “pay $16 million to resolve allegations that it submitted false claims for payment to Medicare and other federal health care programs.”

Register for National Whistleblower Day

According to the settlement agreement, a whistleblower filed a qui tam lawsuit in January of 2019 and alleged that Inform “violated the federal False Claims Act by submitting false claims to Medicare and other federally funded healthcare programs for non-payable, nonallowable laboratory services conducted without a treating physician’s order.” The whistleblower alleged that this behavior was “part of an improper upfront, preorder testing scheme.”

According to the whistleblower, “rather than perform only the test(s) ordered by the treating physician, Inform automatically and systematically ran additional tests, including special stains, without the treating physician’s knowledge, consent, or order, and without a pathologist’s determination of medical necessity.”

The press release contains additional information, stating that with the settlement, “Inform admits that, between 2013 and 2018, it routinely and automatically conducted additional tests on biopsy specimens prior to a pathologist’s review and without an individualized determination regarding whether additional tests were medically necessary.” Thus, the government alleged that Inform caused false claims to be submitted to federal health care programs because some of the testing was medically unnecessary.

For their role in the case, the whistleblower will receive $2,720,000 from the U.S. government and $61,567 from Inform.

“Laboratories that bill for medically unnecessary tests drain funds from Medicare and other federally funded health care programs,” said U.S. Attorney Rachael S. Rollins in the press release. “Prioritizing profit over complying with the law wastes hard earned taxpayer dollars. Companies that engage in this fraudulent conduct will be held accountable.”

Biotronik Inc.

On July 22, the DOJ announced a $12.95 million settlement with Biotronik, Inc., an Oregon-based medical manufacturer. Biotronik will “resolve allegations that it violated the False Claims Act by causing the submission of false claims to Medicare and Medicaid by paying kickbacks to physicians to induce their use of Biotronik’s implantable cardiac devices, such as pacemakers and defibrillators.”

Jeffrey Bell and Andrew Schmid, who were both former “independent sales representatives for Biotronik,” filed a whistleblower lawsuit in March of 2018. They alleged that Biotronik “knowingly caused the submission of false claims for payment to federal healthcare programs by providing remuneration to physicians to induce them to use Biotronik’s” cardiac rhythm management (CRM) devices, according to the settlement agreement. The U.S. government intervened in the whistleblowers’ case in June of 2021.

The U.S. alleged that “Biotronik knowingly paid excessive payments to physicians with a purpose of inducing and rewarding their use of Biotronik’s pacemakers, defibrillators, and other cardiac devices.” In particular, Biotronik allegedly “abused its new employee training program by knowingly paying some of its physician customers to provide excessive employee trainings.” The settlement agreement states that according to written agreements between Biotronik and the physician customers, the physicians, or Training Physicians, “were to be paid a fixed fee of approximately $400.00 each time a Biotronik employee trainee received training during one of the Training Physicians’ CRM implant procedures.”

This practice continued even though “Biotronik’s compliance and training departments warned that Biotronik’s salespeople had too much influence in the selection of Training Physicians, that the Training program and resulting payments were being overutilized, and that the goal of educating Biotronik employees could be achieved without paying Training Physicians.” Biotronik would, “in certain circumstances,” allow “trainees to attend an excessive number of training procedures for which Training Physicians received payment from Biotronik” without an initial assessment of if the trainees needed more training.

In some cases, Biotronik salespeople, which included managers, “intentionally prevented otherwise qualified trainees from successfully completing the Training Program, not because they needed additional training, but rather as a means of ensuring that the trainee could attend more trainings, thereby purportedly justifying additional payments to Training Physicians.” Biotronik also allegedly paid the Training Physicians “for some trainings that either never occurred or were of little or no value to trainees.”

The government also alleged that Biotronik “knowingly paid for lavish meals, entertainment, and travel for certain physicians who are known to Biotronick and the United States with a purpose of inducing and rewarding their use of Biotronik’s pacemakers, defibrillators, and other cardiac devices.”

According to the settlement agreement, “Biotronik paid for winery tours, annual office holiday parties, and lavish meals with certain [physicians] and their guests at high-end restaurants.”

To settle the allegations, Biotronik will pay the U.S. $12,016,594. The company will pay the Medicaid Participating States, which are Arizona, California, Illinois, Missouri, and Nevada a total of $933,406. Altogether, Biotronik will have to pay $12,950,000 in this settlement.

Additionally, Biotronik will pay the two whistleblowers and their counsel $1,250,000 collectively; Bell will receieve $390.000 and Schmid will net $360,000. The whistleblowers’ counsel will receive $500,000 “for statutory fees and costs.”

Healthcare Industry Whistleblowers

Whistleblowers are key to uncovering fraud and corruption in the healthcare industry: fraudulent schemes can be particularly harmful to patients and erode trust in the medical system. In Fiscal Year 2021, qui tam whistleblowers helped the DOJ recover $1.6 billion in settlements. The DOJ highlighted health care fraud as “the leading source of the department’s False Claims Act settlements and judgments.”

Read the Inform Diagnostics, Inc. case press release here. 

Read the Biotronik Inc. case press release here. 

Read more false claims/qui tam news on WNN. 

Tags: False Claims / Qui TamFalse Claims ActFalse claims act rewardsFalse Claims/Qui TamQui Tamqui tam whistleblowers
Previous Post

Longtime Whistleblower Champion Senator Chuck Grassley To Give Keynote Speech at National Whistleblower Day Celebration

Next Post

Panama Papers Whistleblower Gives First Interview

Ana Popovich

Ana Popovich

Ana Popovich is a contributing editor with Whistleblower Network News, where she writes about breaking whistleblower news, healthcare fraud whistleblowers, and Covid-19 fraud whistleblowers. Ana has a B.A. in English from Georgetown University. While at Georgetown, she was the marketing chair of an affinity group and wrote content for the McDonough School of Business’ Business for Impact program. In 2018, Popovich was a public interest legal intern at the whistleblower law firm Kohn, Kohn and Colapinto. 

Next Post
Panama Papers Whistleblower

Panama Papers Whistleblower Gives First Interview

Receive Daily Alerts

Subscribe to receive daily breaking news and legislative developments sent to your inbox.

  • This field is for validation purposes and should be left unchanged.

Most Popular

Advocates Detail Need for SEC Whistleblower Reform

Raytheon Whistleblower Receives $1.5 Million for Alleging Cybersecurity Non-Compliance

Ruling Striking Down Trump Order Targeting Law Firm Seen as Crucial for Whistleblowers

MJH Healthcare Settles Whistleblower Allegations of Postal Rate Fraud for $2 Million

Poll Shows Overwhelming Support for Stronger Whistleblower Laws in Australia, Mirroring Polling in US

Four Whistleblowers Receive $1.3 Million for Alleging Genetic Testing Fraud Scheme

Whistleblower Poll

Whistleblower Poll
Whistleblower Poll

Exclusive Marist Poll: Overwhelming Public Support Among Likely Voters For Increased Whistleblower Protections

byGeoff Schweller
October 6, 2020

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT

STAY INFORMED.
Subscribe to receive breaking whistleblower updates.

  • This field is for validation purposes and should be left unchanged.

About Us

  • About
  • Contact Us
  • Donate
  • Careers

Subscribe

  • Daily Mail
  • Follow us on Twitter
  • YouTube Channel

Contribute

  • Letter to the Editor
  • Submission Guidelines
  • Reprint Guidelines

Your Experience

  • Accessibility Statement
  • Privacy Policy
  • Terms of Use

Help

  • Rules for Whistleblowers
  • Frequently Asked Questions
  • Advertise
Whistleblower Network News

Whistleblower Network News is an independent online newspaper providing our readers with up-to-date information on whistleblowing. Our goal is to be the best source of information on important qui tam, anti-corruption, compliance, and whistleblower law developments. 

Submit an Article

Copyright © 2025, Whistleblower Network News. All Rights Reserved.

This Newspaper/Web Site is made available by the publisher for educational purposes only as well as to give you general information and a general understanding of the law, not to provide specific legal advice. By using this website, you understand that there is no attorney-client relationship between you and the Newspaper/Web Site publisher. The Newspaper/Web Site should not be used as a substitute for competent legal advice from a licensed professional attorney in your state.

Become a Whistleblower Network News Subscriber

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Subscribe to WNN

Retrieve your password

Please enter your username or email address to reset your password.

Subscribe to WNN
RSVP to National Whistleblower Day 2025! July 30, 2025 on Capitol Hill
RSVP NOW

Add New Playlist

No Result
View All Result
  • Exclusives
  • Government
    • False Claims-Qui Tam
    • Federal Employees
    • Intelligence
  • Corporate
    • CFTC & Commodities
    • Dodd-Frank
    • IRS & Tax
    • SEC & Securities
  • Features
  • Legislation
  • International
    • Foreign Corruption
  • Rewards
  • Whistleblower of the Week
  • Environment & Climate
  • Opinion
  • Editorial
  • Employment
    • Sarbanes-Oxley Whistleblowers
    • Retaliation
    • OSHA
  • Make National Whistleblower Day Permanent
  • Media
    • Podcasts
    • Videos
    • Webinars
    • National Whistleblower Day
  • Whistleblower Poll
  • Whistleblower Resources
    • Frequently Asked Questions
    • Resources for Locating An Attorney
    • The New Whistleblowers Handbook

Copyright © 2024, Whistleblower Network News. All Rights Reserved.

Go to mobile version